Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25233110 | 0.87 | AKT1 (0.32) | AKT1 | |
| SCHEMBL29068650 | 0.83 | CTSD (0.33) | CTSDCTSLCTSBCTSS | |
| SCHEMBL25279517 | 0.83 | CTSD (0.33) | CTSDCTSLCTSBCTSS | |
| SCHEMBL22532934 | 0.75 | GAA (0.33) | CTSDCTSLCTSBCTSSAKT1 | |
| SCHEMBL25425223 | 0.73 | CTSD (0.34) | CTSDCTSLCTSBCTSS | |
| SCHEMBL25421396 | 0.73 | CTSD (0.34) | CTSDCTSLCTSBCTSS | |
| SCHEMBL32687873 | 0.72 | NPSR1 (0.33) | AKT1 | |
| SCHEMBL30733418 | 0.72 | AKT1 (0.35) | AKT1 | |
| SCHEMBL25232223 | 0.71 | NPSR1 (0.33) | AKT1 | |
| SCHEMBL31252257 | 0.71 | AKT1 (0.37) | CTSDCTSLCTSBCTSSAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196479-B1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116745292-A | Substituted pyridotriazine compounds and uses thereof | 吉利德科学公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230257389-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257389-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-4196479-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022159387-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257389-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | CTSD 2479/4885CTSL 799/4885CTSB 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.